Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Decoding the human CD4<sup>+</sup> T cell epitope repertoire for Lassa fever virus reveals T cell-based pan-mammarenavirus vaccine candidates.

Cell reports. Medicine·2026

Same author

Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins.

Cell host & microbe·2026

Same author

A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodies.

Npj viruses·2026

Same author

Characterization of atypical Ebola virus disease in ferrets.

PLoS pathogens·2026

Same author

Searching for immune correlates in Lassa vaccine development - workshop report.

NPJ vaccines·2026

Same author

Structural and mechanistic basis for antibody neutralization of the measles fusion protein.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Dec 25, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

A Vaccine against Ebola Virus.

Erica Ollmann Saphire¹

¹La Jolla Institute for Immunology, La Jolla, CA, USA.

|April 4, 2020

Summary

Ervebo is the first licensed vaccine for preventing Ebola virus disease. Administered in a single dose, it has been given to over 200,000 individuals during the 2018-2020 outbreak.

Area of Science:

Vaccinology
Infectious Diseases
Public Health

Background:

Ebola virus disease (EVD) poses a significant global health threat.
The development of effective preventive measures against EVD is crucial.

Purpose of the Study:

To introduce Ervebo, the first licensed vaccine for the prevention of Ebola virus disease.
To highlight its role in combating ongoing EVD outbreaks.

Main Methods:

The vaccine was originally developed by the Public Health Agency of Canada.
Ervebo is administered as a single 1 mL dose.

Main Results:

The vaccine has been administered to over 200,000 people.
It has been deployed during the 2018-2020 EVD outbreak.

More Related Videos

Remote Laboratory Management: Respiratory Virus Diagnostics

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment

Published on: July 19, 2017

Related Experiment Videos

Last Updated: Dec 25, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Remote Laboratory Management: Respiratory Virus Diagnostics

Remote Laboratory Management: Respiratory Virus Diagnostics

Published on: April 6, 2019

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment

Utilization of Capsules for Negative Staining of Viral Samples within Biocontainment

Published on: July 19, 2017

Conclusions:

Ervebo represents a major advancement in EVD prevention.
Its widespread use demonstrates its practical application in outbreak control.